Indoleamine 2,3-dioxygenase/IDO Antibody (700838) [Phycoerythrin]

Human Monocytes were selected from PBMC using MagCellect Human CD14+ Cell Isolation Kit (MAGH105) and cultured overnight with Recombinant Human MCSF (50 ng/mL; 216-MC), Recombinant Human IFN gamma (50 ng/mL; 285-IF) and 50 ng/mL LPS and stained with (A) Mouse Anti-Human Indoleamine 2,3-dioxygenase/IDO PE-conjugated Monoclonal Antibody (Catalog # IC6030P) or (B) Mouse IgG1 isotype control antibody (IC002P) and Mouse Anti-Human CD14 APC-conjugated Monoclonal Antibody (FAB3832A). To facilitate intracellular staining, cells were fixed and permeabilized with FlowX FoxP3/Transcription Factor Fixation & Perm Kit (FC012). Staining was performed using our Staining Intracellular Molecules protocol.

Human myeloid-derived suppressor cells (MDSCs) treated with 10 ng/mL Recombinant Human IL-6 (Catalog # 206-IL) and 10 ng/mL Recombinant Human GM-CSF (Catalog # 215-GM) for 7 days were stained with Mouse Anti-Human Siglec-3/CD33 APC-conjugated Monoclonal Antibody (Catalog # FAB1137A) and either (A) Mouse Anti-Human Indoleamine 2,3-dioxygenase/IDO PE-conjugated Monoclonal Antibody (Catalog # IC6030P) or (B) Mouse IgG1Phycoerythrin Isotype Control (Catalog # IC002P). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with Flow Cytometry Permeabilization/Wash Buffer I (Catalog # FC005). View our protocol for Staining Intracellular Molecules.

SLE sera increase IDO expression in a type I IFN-dependent manner.Endothelial cells (WISH cells) were incubated with A) recombinant IFN-alpha with or without pre-incubation with an IFN alpha/beta receptor blocking antibody (IFNAR ab) and IDO expression analyzed in permeabilized cells by flow cytometry. B) WISH cells were incubated with serum from SLE patients or healthy individuals with or without pre-incubation with an IFNAR ab. The results are presented as percentage increased IDO expression in median fluorescence intensity (MFI) as compared to non-stimulated cells. C) Patients with ongoing type I IFN activity (SLE IFN+) had increased IDO activity as compared to patients with no type I IFN activity (SLE IFN-) and healthy volunteers (HV). D) Patients with ongoing type I IFN activity had decreased serotonin levels as compared to patients with no type I IFN activity and healthy volunteers. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0125109), licensed under a CC-BY license. Not internally tested by R&D Systems.

SLE sera increase IDO expression in a type I IFN-dependent manner.Endothelial cells (WISH cells) were incubated with A) recombinant IFN-alpha with or without pre-incubation with an IFN alpha/beta receptor blocking antibody (IFNAR ab) and IDO expression analyzed in permeabilized cells by flow cytometry. B) WISH cells were incubated with serum from SLE patients or healthy individuals with or without pre-incubation with an IFNAR ab. The results are presented as percentage increased IDO expression in median fluorescence intensity (MFI) as compared to non-stimulated cells. C) Patients with ongoing type I IFN activity (SLE IFN+) had increased IDO activity as compared to patients with no type I IFN activity (SLE IFN-) and healthy volunteers (HV). D) Patients with ongoing type I IFN activity had decreased serotonin levels as compared to patients with no type I IFN activity and healthy volunteers. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0125109), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: Flow
• Clone: 700838
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Phycoerythrin

Indoleamine 2,3-dioxygenase/IDO Antibody (700838) [Phycoerythrin] Summary

• Immunogen: E. coli-derived recombinant human Indoleamine 2,3-dioxygenase/IDO
  Ala2-Gly403
  Accession # P14902
• Specificity: Detects human Indoleamine 2,3-dioxygenase/IDO in direct ELISAs.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: IDO1
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Intracellular Staining by Flow Cytometry 10 uL/10^6 cells

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze.
  • 12 months from date of receipt, 2 to 8 °C as supplied.
• Buffer: Supplied in a saline solution containing BSA and Sodium Azide.
• Preservative: Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Indoleamine 2,3-dioxygenase/IDO Antibody (700838) [Phycoerythrin]

• 3dioxygenase
• EC 1.13.11.52
• IDO
• IDO1
• IDOIDO-1
• INDO
• INDOindole 2,3-dioxygenase
• Indoleamine 2
• indoleamine 2,3-dioxygenase 1
• Indoleamine 2,3-dioxygenase
• indoleamine-pyrrole 2,3 dioxygenase
• Indoleamine-pyrrole 2,3-dioxygenase

Background

Indoleamine 2,3-dioxygenase (also known as IDO) is a heme-containing intracellular dioxygenase catalyzing the degradation of the essential amino acid L-tryptophan to N‑formyl‑kynurenine (1). This degradation is the first and rate-limiting step of the L-kynurenine pathway (2). IDO is widely expressed in dendritic cells, macrophages, microglia, eosinophils, fibroblasts, endothelial cells, and most tumor cells. In immune cells, its expression is mainly induced by cytokines such as IFN-gamma , IFN-alpha , IFN‑ beta , and IL-10. IDO has an antimicrobial function due to its decreasing the availability of the essential amino acid tryptophan in inflammatory environments (3). Recent studies have demonstrated that IDO induces immunosuppression during infection, pregnancy, transplantation, autoimmunity, and neoplasia (3-5).

1. Lewis-Ballester, A. et al. (2009) Proc. Natl. Acad. Sci. USA. 106:17371.
2. Costantino, G. (2009) Expert Opin. Ther. Targets 13:247.
3. Xu, H. et al. (2008) Immunol. Lett. 121:1.
4. Lob, S. et al. (2009) Nat. Rev. Cancer 9:445.
5. Curti, A. et al. (2009) Blood 113:2394.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Indoleamine 2,3-dioxygenase/IDO Antibody (IC6030P)(6)

Publications using IC6030P

• Subayyil, AA;Basmaeil, YS;Kulayb, HB;Alrodayyan, M;Alhaber, LAA;Almanaa, TN;Khatlani, T; Preconditioned Chorionic Villus Mesenchymal Stem/Stromal Cells (CVMSCs) Minimize the Invasive Phenotypes of Breast Cancer Cell Line MDA231 In Vitro International journal of molecular sciences 2023-05-31 [PMID: 37298519] (Flow Cytometry, Human)
• JAP Oliveira, M Gandini, JS Sales, SK Fujimori, MGM Barbosa, VS Frutuoso, MO Moraes, EN Sarno, MCV Pessolani, RO Pinheiro Mycobacterium leprae induces a tolerogenic profile in monocyte-derived dendritic cells via TLR2 induction of IDO J Leukoc Biol, 2020-10-11;0(0):. 2020-10-11 [PMID: 33040382] (Flow Cytometry, Human)
• M Zarobkiewi, W Kowalska, S Chocholska, W Tomczak, A Szyma?ska, I Morawska, A Wojciechow, A Bojarska-J High M-MDSC Percentage as a Negative Prognostic Factor in Chronic Lymphocytic Leukaemia Cancers (Basel), 2020-09-14;12(9):. 9/14/2020 [PMID: 32937740]
• F Abomaray, S Gidlöf, C Götherströ Mesenchymal Stromal Cells Are More Immunosuppressive In Vitro If They Are Derived from Endometriotic Lesions than from Eutopic Endometrium Stem Cells Int, 2017-11-05;2017(0):3215962. 2017-11-05 [PMID: 29230250] (Flow Cytometry, Human)
• LHG Matheus, GM Simão, TA Amaral, RBO Brito, CS Malta, YST Matos, AC Santana, GGC Rodrigues, MC Albejante, EE Bach, MA Dalboni, CP Camacho, H Dellê Indoleamine 2, 3-dioxygenase (IDO) increases during renal fibrogenesis and its inhibition potentiates TGF-? 1-induced epithelial to mesenchymal transition BMC Nephrol, 2017-09-06;18(1):287. 2017-09-06 [PMID: 28877670] (ICC, Canine)
• Lood C, Tyden H, Gullstrand B, Klint C, Wenglen C, Nielsen C, Heegaard N, Jonsen A, Kahn R, Bengtsson A Type I interferon-mediated skewing of the serotonin synthesis is associated with severe disease in systemic lupus erythematosus. PLoS ONE, 2015-04-21;10(4):e0125109. 2015-04-21 [PMID: 25897671] (Flow Cytometry, Human)

Bioinformatics

• Gene Symbol: IDO1
• Uniprot:
  • P14902()